NovaBay Pharmaceuticals’ Aganocide Compound, NVC-422, Featured in Drugs of the Future – msnbc.com

NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), is a clinical-stage biotechnology company developing its pipeline of first-in-class, broad-spectrum, anti-infective Aganocide┬« compounds for the local non-systemic treatment and prevention of …